Safety Profile

Studied in 2 phase 3 clinical trials.1

Solicited Local Adverse Reactions and General Adverse Events Within 7 Days of Vaccination1,4

  Aged 50-59 Years
All Grades/Grade 3a-e
Aged 60-69 Years
All Grades/Grade 3a-e

Aged ≥70 Years
All Grades/Grade 3a-e

Solicited Local Adverse Reactions

SHINGRIX %
n=1315
Placebo %
n=1312
SHINGRIX %
n=1311
Placebo %
n=1305
SHINGRIX %
n=2258
Placebo %
n=2263
Pain 88.4 / 10.3 14.4 / 0.5 82.8 / 6.9 11.1 / 0.5 69.2 / 4.0 8.8 / 0.2
Redness 38.7 / 2.8 1.2 / 0.0 38.4 / 2.6 1.6 / 0.0 37.7 / 3.1 1.2 / 0.0
Swelling 30.5 / 1.1 0.8 / 0.0 26.5 / 0.5 1.0 / 0.0 23.0 / 1.3 1.1 / 0.0

Solicited General Adverse Events

n=1315 n=1312 n=1309 n=1305 n=2252 n=2264
Myalgia 56.9 / 8.9 15.2 / 0.9 49.0 / 5.3 11.2 / 0.8 35.1 / 2.8 9.9 / 0.4
Fatigue 57.0 / 8.5 19.8 / 1.8 45.7 / 5.0 16.8 / 0.8 36.6 / 3.5 14.4 / 0.8
Headache 50.6 / 6.0 21.6 / 1.7 39.6 / 3.7 15.6 / 0.2 29.0 / 1.5 11.8 / 0.4
Shivering 35.8 / 6.8 7.4 / 0.2 30.3 / 4.5 5.7 / 0.3 19.5 / 2.2 4.9 / 0.3
Feverd 27.8 / 0.4 3.0 / 0.2 23.9 / 0.5 3.4 / 0.2 14.3 / 0.1 2.7 / 0.1
GIe 24.3 / 2.1 10.7 / 0.7 16.7 / 0.9 8.7 / 0.6 13.5 / 1.2 7.6 / 0.4

Solicited Local Adverse Reactions and General Adverse Events Within 7 Days of Vaccination1,4

  All Grades/Grade 3a-e

Solicited Local Adverse Reactions

SHINGRIX %
n=1315
Placebo %
n=1312
Pain 88.4 / 10.3 14.4 / 0.5
Redness 38.7 / 2.8 1.2 / 0.0
Swelling 30.5 / 1.1 0.8 / 0.0

Solicited General Adverse Events

n=1315 n=1312
Myalgia 56.9 / 8.9 15.2 / 0.9
Fatigue 57.0 / 8.5 19.8 / 1.8
Headache 50.6 / 6.0 21.6 / 1.7
Shivering 35.8 / 6.8 7.4 / 0.2
Feverd 27.8 / 0.4 3.0 / 0.2
GIe 24.3 / 2.1 10.7 / 0.7
  All Grades/Grade 3a-e

Solicited Local Adverse Reactions

SHINGRIX %
n=1311
Placebo %
n=1305
Pain 82.8 / 6.9 11.1 / 0.5
Redness 38.4 / 2.6 1.6 / 0.0
Swelling 26.5 / 0.5 1.0 / 0.0

Solicited General Adverse Events

n=1309 n=1305
Myalgia 49.0 / 5.3 11.2 / 0.8
Fatigue 45.7 / 5.0 16.8 / 0.8
Headache 39.6 / 3.7 15.6 / 0.2
Shivering 30.3 / 4.5 5.7 / 0.3
Feverd 23.9 / 0.5 3.4 / 0.2
GIe 16.7 / 0.9 8.7 / 0.6
  All Grades/Grade 3a-e

Solicited Local Adverse Reactions

SHINGRIX %
n=2258
Placebo %
n=2263
Pain 69.2 / 4.0 8.8 / 0.2
Redness 37.7 / 3.1 1.2 / 0.0
Swelling 23.0 / 1.3 1.1 / 0.0

Solicited General Adverse Events

n=2252 n=2264
Myalgia 35.1 / 2.8 9.9 / 0.4
Fatigue 36.6 / 3.5 14.4 / 0.8
Headache 29.0 / 1.5 11.8 / 0.4
Shivering 19.5 / 2.2 4.9 / 0.3
Feverd 14.3 / 0.1 2.7 / 0.1
GIe 13.5 / 1.2 7.6 / 0.4

The majority of solicited adverse reactions were mild to moderate (Grade 1 or 2).
Median duration of the above solicited adverse reactions was 2 to 3 days.1-3

  •   aGrade 3 pain defined as significant pain at rest; prevents normal everyday activities.1
  •   bGrade 3 redness and swelling defined as >100 mm in size.3
  •   cGrade 3 myalgia, fatigue, headache, shivering, GI defined as preventing normal activity.1
  •   dFever defined as ≥37.5°C/99.5°F for oral, axillary, or tympanic route, or ≥38°C/100.4°F for rectal route; Grade 3 fever defined as >39.0°C/102.2°F.1
  •   eGI=Gastrointestinal symptoms, including nausea, vomiting, diarrhea, and/or abdominal pain.1


Total vaccinated cohort for safety included all subjects with at least 1 documented dose (n).

Rates observed during 1-year follow-up period1

  SHINGRIX Placebo
SAEs 10.1% 10.4%
Deaths 0.8% 0.9%
pIMDs 0.6% 0.7%

SAE=serious adverse event;

pIMD=potential immune-mediated disease.

Study Analysis:

The safety of SHINGRIX was evaluated by pooling data from 2 placebo-controlled clinical trials involving 29,305 subjects aged 50 years and older who received at least 1 dose of SHINGRIX (N=14,645) or placebo (saline solution) (N=14,660) administered according to a 0- and 2-month schedule. In Studies 1 and 2, data on solicited local and general adverse events were collected using standardized diary cards for 7 days following each vaccine dose or placebo (ie, day of vaccination and the next 6 days) in a subset of subjects (n=4886 receiving SHINGRIX, n=4881 receiving placebo with at least 1 documented dose).1

You may also be interested in:

Only SHINGRIX delivered >90% efficacy against shingles regardless of age in those 50 years and older.1,*

Learn how age-related decline in immunity is a dominant driver of shingles and can lead to a sharp increase in both the incidence and complications of shingles.4-6

See what CDC says about SHINGRIX.

CDC=Centers for Disease Control and Prevention.

*Data from the phase 3 ZOE-50 (≥50 years of age) trial (median follow-up period 3.1 years) and pooled data in individuals ≥70 years of age from the phase 3 ZOE-50 and ZOE-70 trials (median follow-up period 4 years) in subjects who received 2 doses of SHINGRIX (n=7344 and 8250, respectively) or placebo (n=7415 and 8346, respectively). These populations represented the modified Total Vaccinated Cohort, defined as patients who received 2 doses (0 and 2 months) of either SHINGRIX or placebo and did not develop a confirmed case of herpes zoster within 1 month after the second dose.1,7 See study designs on the Efficacy page for details.